Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Atopic Dermatitis: full-pipeline trial registry
55 of 151 indexed Atopic Dermatitis trials are currently recruiting.
Corpus placement: #76 of 28,707 conditions by registered trial count.
151 US clinical trials · 55 currently recruiting · #76 of 28,707 conditions by registered trial count
Atopic Dermatitis: 151 US clinical trials tracked, 55 recruiting.
Atopic Dermatitis is the subject of 151 registered US clinical trials on ClinicalTrials.gov, 55 of them currently open to new participants. 47 are in Phase 3-4 (later-stage) and 66 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 10 of these trials.
Enrollment posture brief
Registry condition atopic-dermatitis
OPEN 55 | RECR 36% | LATE 47 | EARLY 66 | RANK #76 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Acquired Brain Injury (36% recruiting · 11 trials)
Atopic Dermatitis lists 55 open slots (36% of 151 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Atopic Dermatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Atopic Dermatitis recruits in line with its size-band peers.
55 of 151 indexed trials (36.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Atopic Dermatitis trials is spread across many organizations.
Pfizer accounts for 10 of 151 trials (6.6%). 80 distinct sponsors appear on at least one study for this condition label.
-
Typical Atopic Dermatitis enrolment sits around 137 participants.
Median target enrolment is 137 among the 151 trials that report a genuine target (sentinel values excluded). 65 of those (43%) plan for fewer than 100 participants.
-
Atopic Dermatitis research is mostly interventional.
122 interventional and 29 observational studies make up this index (80.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
151 total, page 3 of 4
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
AstraZeneca
NCT04212169
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
Bellus Health Inc. - a GSK company
NCT04693195
A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
Arena Pharmaceuticals
NCT04162769
A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
Pfizer
NCT03356977
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
Pfizer
NCT04664153
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
RAPT Therapeutics
NCT04271514
Scratch Behavior Under Standard of Care
Boston University
NCT03898427
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
Otsuka Pharmaceutical Development & Commercialization
NCT01702181
ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis
University of Rochester
NCT03645057
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Eli Lilly and Company
NCT05372419
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
Janssen Research & Development
NCT04021862
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Corvus Pharmaceuticals
NCT06345404
Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00723489
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
University of California, Davis
NCT00826592
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Bayer
NCT05656911
Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
Novartis
NCT00117377
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
Ichnos Sciences
NCT02683928
Bleach Bath Treatment of Adults With Atopic Dermatitis
University of Rochester
NCT01996150
Clinic-Based Atopic Dermatitis Therapeutic Patient Education
Boston University
NCT04352270
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
Hangzhou Yirui Pharmaceutical Technology Co.
NCT05718921
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
Aclaris Therapeutics
NCT04598269
A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
Yale University
NCT01675232
Secukinumab for Treatment of Atopic Dermatitis
Icahn School of Medicine at Mount Sinai
NCT02594098
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
Organon and
NCT05186805
Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis
Ceragenix Pharmaceuticals
NCT00460083
Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis
Hangzhou Yirui Pharmaceutical Technology Co.
NCT06309355
Molecular and Cellular Characterization of Spongiotic Dermatitis
University of California, Davis
NCT00371163
Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
Ann & Robert H Lurie Children's Hospital of Chicago
NCT04023084
A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis
Provectus Pharmaceuticals
NCT00690807
Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis
Frankel, Amylynne, M.D.
NCT01202149
Bone Health in Patients With Atopic Dermatitis
Mayo Clinic
NCT03800004
A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis
AOBiome
NCT03775434
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
Sun Pharmaceutical Industries
NCT02932891
Steroid-reducing Effects of Crisaborole
Johns Hopkins University
NCT03832010
A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects
LEO Pharma
NCT05099133
Evaluating Treatment Resistant Dermatitis TaroIIR
Wake Forest University Health Sciences
NCT03050294
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
Kymera Therapeutics
NCT06945458
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
Oregon Health and Science University
NCT00806221
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
Amgen
NCT05891119
A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis
Wake Forest University Health Sciences
NCT01049243
Skin Tape Transcriptome Methods in Children
National Jewish Health
NCT04180644
Sweat and Gas Sensor for Healthy Skin and Atopic Dermatitis
Northwestern University
NCT03874039
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
Fougera Pharmaceuticals
NCT01137032
DMT210 Topical Gel in the Treatment of Atopic Dermatitis
Dermata Therapeutics
NCT02949960
Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period
Clinical Research Center of the Carolinas
NCT04008784
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
Pfizer
NCT07172321
Study of Apremilast in Atopic or Contact Dermatitis
Tufts Medical Center
NCT00931242
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Rockefeller University
NCT01149759
Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
Stanford University
NCT01678092
IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis
Mayo Clinic
NCT05372003
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 48 |
| Phase 3 | 28 |
| Phase 4 | 19 |
Top Sponsors
Named interventions
Most-linked intervention names on Atopic Dermatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Atopic Dermatitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Atopic Dermatitis page
151 registered trials, 55 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 55 Atopic Dermatitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Atopic Dermatitis trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atopic Dermatitis condition card totals 151 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.